San Jose, CA (Vocus/PRWEB) January 11, 2011
Osteoporosis represents an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. As per International Osteoporosis Foundation census, more than 200 million people in the world are affected by osteoporosis, of which about 80% are women. Over the next decade, growth in elderly population across the world, and the resultant increase in potential osteoporosis patients, is poised to offer several opportunities for pharmaceutical companies in the osteoporosis therapeutics market. However, with patents of several drugs set to expire, the value of existing treatment products is expected to decline by 2015. A whole new range of products set for launch in the near future would nevertheless offset the decline in revenues, and provide enormous growth potential in the osteoporosis therapeutics market in future.
Following significant growth for several years, the global osteoporosis therapeutics market began witnessing revenue declines in 2009. Key to this is the patent expiry of the erstwhile market-leading drug, Fosamax in major markets. The patent expiry spurred entry of generic variants for the drug that led to revenue erosion in the market. Owing to relatively lower difference among the bisphosphonates drug class in terms of efficacy, patent loss of Fosamax began impacting sales of other bisphosphonates as well. Bisphosphonates have been the treatment standard for osteoporosis for several years, which enabled them to capture sizeable share in the osteoporosis therapeutic market. With the incursion of generics into this drug class, sales from the segment are expected to witness continued declines and lead to overall market declines until novel and more efficacious drugs make their way into the market and capture considerable market share. Revenue declines would also be instigated by further patent losses of current major drugs in the market in the next few years.
The US represents the largest regional market for osteoporosis therapeutics worldwide, as stated by the new market research report on Osteoporosis therapeutics. Europe trails behind the US. Global prevalence of osteoporosis among women continues to rise, providing ample opportunities for future growth in the global osteoporosis market. Current treatments are faced with several safety and efficacy concerns, which translate to tremendous potential for new efficacious drugs to capture considerable market share. Strong pipeline with significant number of drugs in late stage development bode prospective entry of new drugs in to the market, even as many of the existing drugs lose patent protection. These new drugs include bone-tissue resorption inhibitors, SERMs (selective estrogen receptors modulators), cathepsin K inhibitors and calcium modulators. Growth in the market is also expected to be driven by the recent approval of Denosumab, a monoclonal antibody, represents a novel class of drug, recently approved for the treatment of osteoporosis. Denosumab has been approved in the US, EU, Switzerland, Canada, and Australia.
Major players profiled in the report include Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi-Aventis SA, Unigene Laboratories Inc., Warner Chilcott Plc., among others.
The research report titled “Osteoporosis Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the osteoporosis therapeutics markets, current market trends, key growth drivers, overview of major drug classes, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for osteoporosis therapeutics market for the years 2007 through 2015 for the following geographic markets - US, Japan, Europe and Rest of World. Key product segments analyzed include Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others (including Anabolic/Bone-Forming agents such as Tereparatide). Also, a seven-year (2000-2006) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Osteoporosis_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #